Last reviewed · How we verify
NCT00275912
Efficacy, Safety, and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures
Phase 4 trial testing Oxcarbazepine in Epilepsy, Partial Seizures in 60 participants. Completed in 28 September 2007.
28 September 2007
Quick facts
| Lead sponsor | Novartis |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 11 September 2006 |
| Primary completion | 28 September 2007 |
| Estimated completion | 28 September 2007 |
| Sites | 5 locations across Russia |
Drugs / interventions tested
- Oxcarbazepine — full drug profile →
Conditions studied
- Epilepsy, Partial Seizures — all drugs for Epilepsy, Partial Seizures →
Sponsor
Novartis — full company profile →
Who can join
Adults 6 Months to 17, any sex, with Epilepsy, Partial Seizures. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is aimed to collect additional data regarding the efficacy in reducing the frequency of partial seizures, as well as the safety and tolerability, of oxcarbazepine monotherapy in children.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00275912
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Oxcarbazepine
Trials testing the same drug.
- NCT06849219 — Comparison of Oxcarbazepine Versus Carbamazepine in the Management of Trigeminal Neuralgia · Phase 4 · active not recruiting
- NCT05697614 — The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children · Phase 4 · unknown
- NCT05450978 — Physiological-based Pharmacokinetics Approach to Medication Exposure During Pregnancy and Breastfeeding · recruiting
- NCT04996199 — Comparision Efficacy of Carbamazepine & Oxcarbazepine in the Treatment of Trigeminal Neuralgia- a Randomised Clinical Tr · Phase 4 · unknown
- NCT03695094 — A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Pad · Phase 1 · completed
Other Novartis trials
Trials by the same sponsor.
- NCT06595069 — A Real-world Study to Assess the Characteristics and Long-term Effectiveness of Inclisiran in Chinese Adult Patients · completed
- NCT06632730 — Therapeutic Management and Use of Resources and Costs of Spinal Muscular Atrophy in Spain · completed
- NCT06395909 — A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis · completed
- NCT06516029 — Real-World Evaluation of Patient Characteristics and Treatment Patterns Among Patients With CML-CP Treated With Ascimini · completed
- NCT06644638 — Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple S · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00275912 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Novartis
- Last refreshed: 23 February 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00275912.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing